Inhibition of Choroidal Neovascularization by Adenovirus-Mediated Delivery of Short Hairpin RNAs Targeting VEGF as a Potential Therapy for AMD
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: Choroidal neovascularization (CNV) is the leading cause of blindness in age-related macular degeneration (AMD). Several lines of evidence implicate increased levels of vascular endothelial growth factor (VEGF) in retinal pigment epithelium (RPE) from patients with AMD. Current approaches to attenuate VEGF or its receptors, including the use of small interfering (si)RNA, show significant promise, but still have limited efficacy and require repeat administrations, using procedures associated with multiple complications. The goal of this study was to develop an approach for long-term endogenous expression of short hairpin (sh)RNA that would significantly attenuate VEGF and hence act as a potential therapy for AMD. METHODS: Several shRNAs expressed from recombinant adenovirus were developed. These shRNAs were expressed in human RPE cells in the presence of adenovirus vectors overexpressing VEGF, and the amount of VEGF attenuation was evaluated. Adenovirus vectors expressing VEGF were subsequently injected into the subretinal space of mice, and induction of CNV was measured in the presence of adenovirus vectors expressing shRNA targeting VEGF. RESULTS: Potent shRNA sequences were identified that were able to silence VEGF in human RPE cells. When expressed from adenovirus backbones, these shRNA constructs silenced VEGF by 94% at a 1:5 molar ratio (VEGF to shRNA) and 64% at a 1:0.05 molar ratio. Adenovirus vectors expressing high levels of VEGF could induce CNV in mice within 5 days. Co-injection of VEGF-expressing viruses into mice with shRNA targeting VEGF led to a substantial (84%) reduction in CNV. CONCLUSIONS: shRNA targeting VEGF from adenovirus vectors allows potent attenuation of VEGF and prevents CNV. This approach shows promise as a therapy for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“For example, in a phase III trial of pegaptanib, patients received intravitreal injections every 6 weeks for 48 weeks to achieve a 15% benefit over sham subconjunctivally injected patients.(16) Intravitreal injections are invasive, with the potential of endophthalmitis, retinal detachment, and cataract.”
BackgroundVEGF links hippocampal activity with neurogenesis, learning and memory
Cao, L., Jiao, X., Zuzga, D. S., Liu, Y., Fong, D. M., Young, D., & During, M. J. (2004) · Nature Genetics · doi:10.1038/ng1395 · Cited by 850
Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., & Maguire, A. M. (1996) · Nature Medicine · doi:10.1038/nm0696-649 · Cited by 316
Chévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M. Y., & Hurwitz, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1883 · Cited by 143 · cited 3×
“nificant toxicity, with efficacy lasting for more than 38 months.(27) Mild inflammation that can be managed is observed, however, in approximately 25% of patients.”
BackgroundMethod
Cited by
Cashman, S. M., Ramo, K., & Kumar-Singh, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019078 · Cited by 118
“We selected adenovirus as a gene delivery vector because we have previously found it to be an efficient vector for delivery of transgenes to ocular tissues [20,34,35] as well as the observation that adenovirus has been found to be safe in several ocular gene therapy trials [36,37,38].”
BackgroundSelf-citationNon-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
“Adenovirus Choroidal neovascularization and age-related macular degeneration shRNAs targeting VEGF C57BL/6j mice Subretinal injection [35]”
BackgroundGene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Exploring the role of VEGF in Indian age-related macular degeneration
Sharma, K., Sharma, N. K., Singh, R., & Anand, A. (2015) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.220408 · Cited by 16
Metadata
- Authors
- Cashman, S. M., Bowman, L., Christofferson, J., & Kumar-Singh, R.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2006-08-01
- Volume
- 47
- Issue
- 8
- Pages
- 3496
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2019950862
- Cited by
- 60
- References
- 4
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Choroidal Neovascularization by Adenovirus-Mediated Delivery of Short Hairpin RNAs Targeting VEGF as a Potential Therapy for AMD. https://app.cochat.ai/papers/10.1167/iovs.05-1610
- The paper
- Cashman, S. M., Bowman, L., Christofferson, J., & Kumar-Singh, R. (2006). Inhibition of Choroidal Neovascularization by Adenovirus-Mediated Delivery of Short Hairpin RNAs Targeting VEGF as a Potential Therapy for AMD. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.05-1610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.